58 related articles for article (PubMed ID: 23537545)
1. [The research progress of epidermal growth factor receptor tyrosine kinase inhibitor in pulmonary fibrosis].
Sun J; Gao ZC
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jan; 36(1):53-6. PubMed ID: 23537545
[No Abstract] [Full Text] [Related]
2. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
Suzuki H; Aoshiba K; Yokohori N; Nagai A
Cancer Res; 2003 Aug; 63(16):5054-9. PubMed ID: 12941834
[TBL] [Abstract][Full Text] [Related]
3. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats.
Rice AB; Moomaw CR; Morgan DL; Bonner JC
Am J Pathol; 1999 Jul; 155(1):213-21. PubMed ID: 10393853
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
5. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.
Budman DR; Soong R; Calabro A; Tai J; Diasio R
Anticancer Drugs; 2006 Sep; 17(8):921-8. PubMed ID: 16940802
[TBL] [Abstract][Full Text] [Related]
6. Tannic acid, a potent inhibitor of epidermal growth factor receptor tyrosine kinase.
Yang EB; Wei L; Zhang K; Chen YZ; Chen WN
J Biochem; 2006 Mar; 139(3):495-502. PubMed ID: 16567414
[TBL] [Abstract][Full Text] [Related]
7. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
[TBL] [Abstract][Full Text] [Related]
8. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin.
Wang P; Tian Q; Liang ZX; Yang Z; Xu SF; Sun JP; Chen LA
Chin Med J (Engl); 2010 Aug; 123(16):2259-64. PubMed ID: 20819676
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
12. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.
Liechti C; Séquin U; Bold G; Furet P; Meyer T; Traxler P
Eur J Med Chem; 2004 Jan; 39(1):11-26. PubMed ID: 14987830
[TBL] [Abstract][Full Text] [Related]
13. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
15. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868.
Simpson BJ; Bartlett JM; Macleod KG; Rabiasz G; Miller EP; Rae AL; Gordge P; Leake RE; Miller WR; Smyth J; Langdon SP
Br J Cancer; 1999 Mar; 79(7-8):1098-103. PubMed ID: 10098742
[TBL] [Abstract][Full Text] [Related]
17. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
Hirata A; Ogawa S; Kometani T; Kuwano T; Naito S; Kuwano M; Ono M
Cancer Res; 2002 May; 62(9):2554-60. PubMed ID: 11980649
[TBL] [Abstract][Full Text] [Related]
18. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Bunn PA; Dziadziuszko R; Varella-Garcia M; Franklin WA; Witta SE; Kelly K; Hirsch FR
Clin Cancer Res; 2006 Jun; 12(12):3652-6. PubMed ID: 16778092
[No Abstract] [Full Text] [Related]
19. Cytoskeletal and morphological changes associated with the specific suppression of the epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid carcinoma.
Nelson JM; Fry DW
Exp Cell Res; 1997 Jun; 233(2):383-90. PubMed ID: 9194500
[TBL] [Abstract][Full Text] [Related]
20. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
